Observational studyHeadache2026
Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.
Observational study in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study.Advances in therapy · 2026Observational
- Results from TRIUMPH [EUROPE], a Real-World Observational Study on the 3-Month Effectiveness of Galcanezumab Versus Traditional Oral Migraine Preventive Medications.Pain and therapy · 2026Article
- Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.Neurology international · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study assesses the 3-month effectiveness of the calcitonin gene-related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications.
backgroundStudies comparing the effectiveness of calcitonin gene-related peptide monoclonal antibodies versus traditional oral migraine preventive medications are limited. However, such comparisons in real-world settings are useful for decision-making by patients, healthcare providers, and policymakers.
methodsTRIUMPH is an ongoing, international, prospective observational cohort study of adult patients with migraine, initiating or switching to new preventive medication with a focus on galcanezumab versus traditional oral migraine preventive medications. Data for this analysis were collected from February 25, 2020, through February 9, 2023. All treatment decisions were at the physicians' discretion. The primary outcome was a 3-month response based on reductions in physician-recorded monthly migraine headache days: ≥50% (episodic migraine) or ≥30% (chronic migraine). The difference in the proportion of responders between treatments was assessed after adjusting for baseline cohort differences.
resultsOf 2813 patients, 1105 received galcanezumab and 1293 received traditional oral migraine preventive medications. The weighted response rate at 3 months was greater with galcanezumab versus traditional oral migraine preventive medications (46.6% vs. 34.5%; p < 0.001). Additional 3-month mean changes from baseline for galcanezumab versus traditional oral migraine preventive medications included a reduction in monthly migraine headache days (-5.7 [95% confidence interval (CI), -6.2 to -5.2] vs. -4.1 [95% CI, -4.5 to -3.7]), and an improvement in Migraine-Specific Quality of Life-Role Function Restrictive score (19.4 [95% CI, 17.6-21.3] vs. 10.2 [95% CI, 8.6-11.8]), respectively (both p < 0.001).
conclusionFindings from this study showed that patients receiving galcanezumab had greater treatment effectiveness after 3 months than those receiving traditional oral migraine preventive medications across multiple measures, including migraine headache days, various responder rate thresholds, change in Migraine-Specific Quality of Life-Role Function Restrictive scores, and types of migraine. These findings are representative of clinical practice settings and may help physicians in making treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.